Mobia Medical Appoints Independent Director Myriam J. Curet, M.D.

What Happened

• Mobia Medical, Inc. filed an 8-K (Aug 3, 2026) reporting that its Board increased from seven to eight members and appointed Myriam J. Curet, M.D. as a Class II director effective July 30, 2026. Her term expires at Mobia’s 2028 annual meeting of stockholders (or until her successor is elected or earlier death, resignation, or removal). The Board determined Dr. Curet qualifies as an independent director under SEC and Nasdaq rules.

Key Details

• Board change: size increased from seven to eight members; Dr. Curet appointed July 30, 2026.
• Term: Class II director with term expiring at the 2028 annual meeting.
• Background: Former Executive Vice President & Chief Medical Officer at Intuitive Surgical (retired March 2026); Clinical Professor of Surgery at Stanford since 2015; current board roles at Inspire Medical Systems (since Dec 2023) and Stereotaxis (since July 2021).
• Governance & compensation: No related-party transactions reported; she will be paid under Mobia’s non-employee director compensation program and Mobia expects to enter its standard indemnification agreement with her.

Why It Matters

• The appointment adds an independent director with extensive clinical and medical-device leadership experience, strengthening the board’s clinical and industry expertise. For investors, this is a governance update that may influence oversight of clinical strategy, product development, and regulatory matters; the filing contains no related-party transactions and states standard director compensation will apply.